My research interests primarily focus on breast cancer, lung cancer and early drug development.
Fulvestrant Plus Vistusertib vs Fulvestrant Plus Everolimus vs Fulvestrant Alone for Women With Hormone Receptor-Positive Metastatic Breast Cancer: The MANTA Phase 2 Randomized Clinical Trial. JAMA Oncol (2019). PMID: 31465093
Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer: A Phase 1 Study. JAMA Oncol (2019) 5(1):74-82. PMID: 30242306
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. N Engl J Med (2018) 379(22):2108-2121. PMID: 30345906
Cancer Immune Therapy
I lead the cancer immunotherapy group at Barts with Professor Thomas Powles, overseeing clinical and translational research on immune checkpoint inhibitors and other immune strategies. The group currently runs more than 10 early clinical trials of single agent or combination cancer immunotherapy treatments, focusing on breast, genitourinary and thoracic cancers.
We are now researching epigenetic 'signatures' of different cancers in order to treat patients with the right medicine for their specific disease. We focus on the role of epigenetics in therapeutic resistance. The aim is to match medicines to patients and reduce the number of patients needlessly subjected to uncomfortable side effects. During this genetic and epigenetic mapping, we also aim to find new cancer-specific targets for drug development.
Novel DNA Damage and Stability Biomarkers and Therapeutic Targets
Over the next 5 years, a variety of novel DDR and chromatin maintenance mechanisms will be validated and, in collaboration with the newly appointed Chairs in Drug Discovery and Medicinal Chemistry, potential inhibitors for synthetic lethality strategies will be identified.
Trials Targeting Therapeutic Resistance
Two international window-of-opportunity trials that Professor Schmid leads focus on establishing the role of targeting the androgen receptor (AR) in early breast cancer, using the novel anti-androgen Enzalutamide:
I also lead a national clinical trial that investigates whether the addition of the HSP27-targeting antisensce oligoneucleotide Apatorsen to chemotherapy can improve the outcome of patients with squamous cell lung cancers.
These trials are supported by NIHR and CRUK funding to the Barts/Brighton Experimental Cancer Medicine Centre. UK recruitment is also supported by the NIHR Cancer Research Network and the UK Experimental Cancer Medicine Centre network.
Our international collaborative group studies circulating biomarkers for screening, diagnosis, patient management and surveillance of breast cancers. The programme includes:
A phase Ib/II study of xentuzumab, an IGF-neutralising antibody, combined with exemestane and everolimus in hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer Schmid P, Sablin MP, Bergh J et al. Breast Cancer Research (2021) 23(7)
Glembatumumab vedotin for patients with metastatic, gpNMB overexpressing, triple-negative breast cancer (“METRIC”): a randomized multicenter study Vahdat LT, Schmid P, Forero-Torres A et al. npj Breast Cancer (2021) 7(7)
Immune analysis of lymph nodes in relation to the presence or absence of tumor infiltrating lymphocytes in triple-negative breast cancer Quintana Á, Peg V, Prat A et al. European Journal of Cancer (2021) 148(7) 134-145
Pembrolizumab plus eribulin in hormone-receptor–positive, HER2-negative, locally recurrent or metastatic breast cancer (KELLY): An open-label, multicentre, single-arm, phase Ⅱ trial Pérez-García JM, Llombart-Cussac A, G. Cortés M et al. European Journal of Cancer (2021) 148(7) 382-394
Sacituzumab govitecan in metastatic triple-negative breast cancer Bardia A, Hurvitz SA, Tolaney SM et al. New England Journal of Medicine (2021) 384(7) 1529-1541
First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors Falchook G, Infante J, Arkenau HT et al. EClinicalMedicine (2021) 34(7)
Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial Winer EP, Lipatov O, Im SA et al. The Lancet Oncology (2021) 22(7) 499-511
Emerging drugs for the treatment of triple-negative breast cancer: a focus on phase II immunotherapy trials Hall PE, Schmid P Expert Opinion on Emerging Drugs (2021) (7)
Association of pathologic complete response with long-term survival outcomes in triple-negative breast cancer: A meta-analysis Huang M, O'Shaughnessy J, Zhao J et al. Cancer Research (2020) 80(7) 5427-5434
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial Cortes J, Cescon DW, Rugo HS et al. The Lancet (2020) 396(7) 1817-1828For additional publications, please click here